Ｐａｇｅ 148109 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼FDA MedWatch- Avast Socabricfodia 08/7/18(金) 12:03 ─────────────────────────────────────── ■題名 ： FDA MedWatch- Avast ■名前 ： Socabricfodia <adsfhadh@gmail.com> ■日付 ： 08/7/18(金) 12:03 ■Ｗｅｂ ： http://msn.com -------------------------------------------------------------------------
| ROCKVILLE, Md., July 14, 2008--Genentech, Inc. cultured healthcare professionals of blasts of divers cases of microangiopathic hemolytic anemia (MAHA) in patients with through-and-through tumors receiving Avastin in parathesis with sunitinib malate. Avastin is not approved for use in solution with sunitinib malate and this parathesis is not recommended. Twenty-five patients were enrolled in a inject I portion-escalation read combining Avastin and sunitinib malate. The examination consisted of 3 cohorts using a unwavering dosage of Avastin at 10mg/kg/IV every 2 weeks and escalating dosages of sunitinib that listd 25, 37.5, and 50 mg orally quotidian premised in a 4 weeks on/ 2 weeks off schedule. Five fo 12 patients at the highest sunitinib dosage plain exhibited laboratory findings accordance with MAHA. Two of these cases were considered sober with show of thrombocytopenia, anemia, reticulocytosis, reductions in serum haptoglobin, schistocytes on tangential defile, sensible increases in sreum creatinine knock downs, and sober hypertension, reversible latter leukoencephalopathy syndrome, and proteinuria. The findings in these two cases were reversible within three weeks upon discontinuation of both drugs without additional interventions. Healthcare professionals should blast cases of MAHA or any sober adverse events suspected to be associated with the use of Avastin. |